Priveterra Acquisition Corp.
AEON · NYSE
NO ACTION REQUIRED
Nothing left to do
The purchase completed and the shares became shares in the company it bought. There is no deadline left to miss.
Cash at settlement
No cash-per-share figure was filed for this vehicle before it finished.
Last close
Daily close
No price history on file yet — daily closes accumulate from the market data feed.
Trust settled · There is no line to draw here. This vehicle has finished: the cash was paid back or spent closing the deal, so the last filed figure describes an account that no longer exists and would be a floor under nothing.
SpacBrain’s read
Trust settled
The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).
In plain terms
- What it is
- A SPAC from Priveterra Sponsor, LLC, listed on NYSE in February 2021.
- What it's doing now
- It agreed to buy AEON Biopharma, Inc., a clinical-stage biopharmaceutical company company. That purchase completed, and it stopped being a SPAC — the shares became shares in the business it bought.
- What you should know
- This SPAC has finished. The purchase completed, and the shares became shares in the company it bought — anyone who wanted the cash instead asked for it at the vote, so there is no cash left here to claim and no deadline left to miss.
At a glance
- Where it stands
- Closed (deSPAC)
- The business it bought
- AEON Biopharma, Inc. — Biopharma AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology …
- Industry
- Health Care — clinical-stage biopharmaceutical company
- Deal value
- not stated in the filings we hold
- Price vs cash at settlement
- no live price on file
- Cash in trust when it settled
- not yet extracted into a snapshot — the filings below may state it
- the last trust total filed while this was still a SPAC — the account has since been paid out or used to close the deal
- IPO
- 11 February 2021
- size not on file
- Headquarters
- 130 VANTIS DRIVE, ALISO VIEJO, CA, 92656
- registered in Delaware
- Lead underwriter
- not extracted from the prospectus yet
- Key officers
- Thunen Shelley B (Director) · PALMISANO ROBERT J (Director) · Forth Marc (Director)
- Listed securities
- AEON common
This vehicle has finished, so there is no window to file a cash-per-share figure for and none will follow. No estimate is shown in its place.
Nothing dated is on file. That is an absence in the record, not a statement that nothing is coming.
Yield to redemption
Nothing left to redeem — no yield to compute.
This SPAC has finished — its trust was paid back or used to close the deal, so there is nothing left to redeem and no yield to compute. A yield to redemption is a claim that you can hand these shares back for the trust cash. That account is closed, so this page will not print a number here.
What happened to the cash
The reasoning behind the verdict above, in the order the filings establish it.
- The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).
What has happened, and what is coming
1 dated milestoneEvery dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.
- 11 February 2021IPOpassed
IPO size not on file
The deal
terms as filedWhat it is buying, on what terms, and how much of the combined company new shares take from you.
- closedHealth Care
What AEON Biopharma, Inc. does — read from aeonbiopharma.com on 26 August 2026
AEON Biopharma is dedicated to advancing access to therapeutic botulinum toxins through biosimilarity. The company is developing ABP-450 (prabotulinumtoxinA) as a branded biosimilar to BOTOX®, aiming to broaden treatment access for neuromuscular conditions by leveraging the FDA’s biosimilar pathway and an established manufacturing platform.
biopharmaceuticalstherapeutic botulinum toxinDeal structureSEC-primary — BCA 8-K / S-4 / DEFM14A- PIPE
- ≈ $7M · unsourced
- Min-cash condition
- $40M
PIPE terms — instrument, coupon, conversion price and any reset floor — are not sourced for this deal. The size above is itself unsourced — a stored figure no filing we hold states — so neither the size nor the terms should be read as cited.
The score
deterministic, from filed fieldsAEON is not in the scored universe, so no score is shown. A withheld score is a fact about the record, not a verdict about the company.
The score is only published for names that carry both a price and a filed cash-per-share figure — 292 of the tracked fleet today. The rest keep an empty dial rather than a modelled one, and fill in by themselves as the fields land.
The company
from SEC filingsRead the full profile
Priveterra Acquisition Corp. was a blank-check company whose common stock traded on the New York Stock Exchange under the ticker AEON. The company priced its initial public offering on February 11, 2021, under SEC file number 333-252310 and SIC industry code 2834 (Pharmaceutical Preparations), with shares registered for cash in the S-1 filing dated January 21, 2021. Its blank-check status was stated in the registrant's own prospectus filed as 424B4 on the same pricing date. The company completed a business combination and ceased filing as a blank-check vehicle, with the closing established by an 8-K filed July 27, 2023, reporting Item 5.06 "Change in Shell Company Status." EDGAR now files SEC CIK 0001837607 under the name AEON Biopharma, Inc.
Material findings
from the full read of every filingEvery document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.
This summary is drawn from the cover page and cautionary note of the report; the financial statements are not covered here. The quarter's figures and the July 2026 financing are stated in the company's earnings release filed the same day (accession 0001837607-26-000061).
Cash on the balance sheet at quarter end was $3.4 million; the runway into Q1 2027 depends on the July financing, and the $34.0 million of milestone warrant proceeds is contingent on both milestones and holder exercise. No clinical study for ABP-450 has been agreed with the FDA yet.
Sections 1003(a)(i) and (ii) are the stockholders' equity tests, so regaining compliance means the equity deficiency that put the company on the noncompliant list has been cured rather than merely deferred. Removal of the .BC suffix restores normal quoting and takes away the visible distress marker that keeps some brokers and index products away. For former Priveterra holders it removes near-term delisting risk, though the filing is explicit that a further breach would restart the process.
The arithmetic reveals the price: about $1.5 million of gross proceeds for 4,696,102 shares implies roughly 32 cents a share. The raise is therefore small in dollars and very large in shares, and the two milestone warrant tranches the representative exercised in full - 6,403,290 shares each, about 12.8 million together - stack substantial further potential issuance on top. That is the defining pattern for a company financing itself off a depressed share price, and existing holders absorb the dilution.
A combined offering price of about 32 cents is the operative number, and the structure compounds it: roughly 42.7 million shares and pre-funded warrants in the base deal, each carrying a two-year and a five-year milestone warrant, struck at $0.3221 and $0.3704, plus the over-allotment. Pre-funded warrants exercise at $0.0001 so they are economically shares already. The milestone warrants add contingent issuance stretching five years out, on a share count already many times the offering itself.
A 15.79% coupon that cannot be prepaid until April 2030 is distress pricing - the company has locked in four years of compounding interest it cannot refinance away, and the note converts into stock on top. True-Up Warrants adjust the investor's share count if the price falls, so the dilution ratchets downward with the equity. Against 26.3 million shares outstanding, the 4,616,924-share issuance alone is roughly 18% before any conversion.
Show 7 more material filings
The company needs more authorized stock than it has: the increase is described as necessary to permit issuance of the shares underlying the convertible notes and of 16,000,000 Contingent Consideration Shares that become issuable on milestones set out in the December 12, 2022 Business Combination Agreement. Holders are therefore being asked to enlarge the ceiling and compress the share count in the same sitting, and a one-third quorum means a modest turnout can carry both.
The target's holders end up with between 70.4% and 77.0% of the combined company depending on how much of the trust survives redemptions, so Priveterra's public shareholders are left with a minority position whose size they cannot control individually. Interim financing arrangements are folded into that calculation, meaning new investors are being brought in ahead of closing on terms that further compress the public stake. Redemption at pro rata trust value remains the alternative for holders who prefer cash to a stub in a clinical-stage aesthetics business.
The Merger Consideration is computed on an as-converted basis that pulls three separate instruments into the common stock first: AEON's warrants exercisable for preferred are exercised, the preferred converts into common under AEON's governing documents, and AEON's convertible notes convert into common under their own terms, plus any common issued in the Subsidiary Merger. The 39,913,926 registered shares are therefore spread across a denominator that only exists at the effective time. Board approval is again stated as by all members voting on the transaction.
This version was filed four days after the business combination agreement was amended, so it is where those amended terms reach a holder. The Merger Consideration is computed on an as-converted basis that first exercises AEON's warrants over preferred stock, converts the preferred into common under AEON's governing documents, and converts AEON's convertible notes into common under their own terms, plus any common issued in the Subsidiary Merger. Board approval is stated as by all members voting on the transaction rather than by the full board.
36,151,237 shares is the registered ceiling at this version, and later amendments to the same registration statement raise it — so the dilution a Priveterra holder faces grew while the transaction was pending. The Merger Consideration is computed on an as-converted basis that first exercises AEON's warrants over preferred stock, converts the preferred into common under AEON's governing documents, and converts AEON's convertible notes into common, so the denominator is assembled at the effective time rather than known now.
The approval language is qualified in a way most filings are not: the cover states that all of the members of the Priveterra board voting on the transaction approved the Business Combination Agreement, rather than that the board approved it unanimously. AEON's share count is computed on an as-converted basis that folds in warrants exercisable for AEON preferred stock, the conversion of that preferred into common, and the conversion of AEON's outstanding convertible notes — so the 36,151,237 ceiling already absorbs instruments that are not common stock today.
The approval language is qualified: the cover states that all of the members of the Priveterra board voting on the transaction approved the Business Combination Agreement, rather than that the board approved it unanimously. The AEON share count is computed on an as-converted basis folding in warrants exercisable for AEON preferred stock, the conversion of that preferred into common, the conversion of AEON's convertible notes, and any AEON common issued in connection with a Subsidiary Merger — so the ceiling already absorbs instruments that are not common stock today.
Filings
live EDGAR feedEverything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.
What changed: Q2 2026 10-Q of AEON Biopharma, Inc. (NYSE American: AEON), with 49,882,790 shares of Class A common stock outstanding as of August 6, 2026. Why it matters: This summary is drawn from the cover page and cautionary note of the report; the financial statements are not covered here. The quarter's figures and the July 2026 financing are stated in the company's earnings release filed the same day (accession 0001837607-26-000061).
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Exhibit 99.1 to an 8-K of AEON Biopharma, Inc. (NYSE American: AEON): the August 12, 2026 press release reporting Q2 2026 results. Cash and equivalents were $3.4 million at June 30, 2026, which excludes approximately $13.6 million of net upfront proceeds from an underwritten public offering completed in July 2026; the company describes that offering as a $15.3 million financing with milestone warrants that could produce up to an additional $34.0 million of gross proceeds on full cash exercise, and states the upfront proceeds are expected to fund operations into the first quarter of 2027. Why it matters: Cash on the balance sheet at quarter end was $3.4 million; the runway into Q1 2027 depends on the July financing, and the $34.0 million of milestone warrant proceeds is contingent on both milestones and holder exercise. No clinical study for ABP-450 has been agreed with the FDA yet.
What changed: AEON Biopharma, Inc., the Priveterra Acquisition Corp. successor, said that on August 3, 2026 it received a letter from NYSE Regulation confirming it has regained compliance with the NYSE American continued listing standards in Part 10 of the Company Guide, having resolved the previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii). The company expects the below compliance indicator to be removed from its Class A trading symbol and to come off NYSE American's published list of noncompliant issuers. It remains subject to the continued listing standards. Why it matters: Sections 1003(a)(i) and (ii) are the stockholders' equity tests, so regaining compliance means the equity deficiency that put the company on the noncompliant list has been cured rather than merely deferred. Removal of the .BC suffix restores normal quoting and takes away the visible distress marker that keeps some brokers and index products away. For former Priveterra holders it removes near-term delisting risk, though the filing is explicit that a further breach would restart the process.
What changed: AEON Biopharma, Inc., the Priveterra Acquisition Corp. successor, reported that on July 23, 2026 it issued and sold 4,696,102 Class A shares to the underwriters on the representative's partial exercise of the over-allotment option under the July 15, 2026 public offering, for gross proceeds of about $1.5 million and net proceeds of about $1.4 million after discounts and commissions. Lake Street Capital Markets was representative and had already exercised in full the option portion covering the two-year and five-year milestone warrants, each over 6,403,290 shares. Why it matters: The arithmetic reveals the price: about $1.5 million of gross proceeds for 4,696,102 shares implies roughly 32 cents a share. The raise is therefore small in dollars and very large in shares, and the two milestone warrant tranches the representative exercised in full - 6,403,290 shares each, about 12.8 million together - stack substantial further potential issuance on top. That is the defining pattern for a company financing itself off a depressed share price, and existing holders absorb the dilution.
Show the other 10 filings
What changed: AEON Biopharma, the Priveterra Acquisition successor, signed an underwriting agreement on July 13, 2026 with Lake Street Capital Markets for a public offering of 17,851,599 Class A shares and pre-funded warrants over 24,837,008 shares, each with one two-year and one five-year milestone warrant. The combined offering price was $0.3221 per share with warrants and $0.3220 per pre-funded warrant with warrants. Why it matters: A combined offering price of about 32 cents is the operative number, and the structure compounds it: roughly 42.7 million shares and pre-funded warrants in the base deal, each carrying a two-year and a five-year milestone warrant, struck at $0.3221 and $0.3704, plus the over-allotment. Pre-funded warrants exercise at $0.0001 so they are economically shares already. The milestone warrants add contingent issuance stretching five years out, on a share count already many times the offering itself.
The sponsor
The people who set this company up, what they have done before, and the advisers around the deal.
Priveterra Sponsor, LLCnamed as sponsor in this SPAC’s filings — but with no researched track record behind it yet.
A missing score, not a score of zero — why
A Sponsor Score is only published once the sponsor’s prior vehicles have been verified on EDGAR and their post-close outcomes priced. That record does not exist for this sponsor yet, so no number and no tier is shown. That is a missing score, not a score of zero — and not a neutral 50 either.
Coverage so far: 301 of 1282 tracked SPACs (23%) are attached to a scored sponsor. This card fills in by itself as the research lands.
The record
The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.
Show the reference detail
Unit structure
from 424B4 0001104659-26-083680
Trading & liquidity
Company profile
Directors & officers
- Thunen Shelley BDirector
- PALMISANO ROBERT JDirector
- Forth MarcDirector
- FISCHER JOSTDirector
- Carter Eric GDirector
- Bencich JohnCHIEF FINANCIAL OFFICER
- Oh ChadCHIEF MEDICAL OFFICER
- LYNCH TIMOTHY P10% owner
Institutional holders
from SC 13G/13DFunds that have declared a stake above 5%. Heavy ownership by arbitrage funds usually means heavy cash-outs at the next vote.
Show the declared stakes
8 filers with a stake on file · 0 re-affirmed in the last 12 months. A stake with no amendment since is the filer’s last word on it, not proof it is still held — and percentages filed in different years are percentages of different floats, because this vehicle’s share count collapses at every redemption.
- Daewoong Co., Ltd24.0% · SC 13DJul 28, 2023 stale
- Polar Asset Management Partners Inc.9.9% · SC 13GFeb 14, 2024 stale
- Atalaya Capital Management LPwith 1 other reporting person on the same schedule9.9% · SC 13GJul 31, 2023 stale
- Blue Owl Capital Holdings LP8.4% · SC 13GNov 14, 2024 stale
- Strathspey Crown Holdings Group, LLC5.5% · SC 13D/AAug 22, 2023 stale
- Empyrean Capital Partners, LPwith 2 other reporting persons on the same schedule5.1% · SC 13G/AFeb 14, 2024 stale
- GLAZER CAPITAL, LLCwith 1 other reporting person on the same schedule3.0% · SC 13G/AJun 12, 2023 stale
- Saba Capital Management, L.P.with 1 other reporting person on the same schedule0.0% · SC 13G/AJul 20, 2023 stale
One line per filer, not per reporting person: a joint schedule names the management company, its funds and often the individual who controls them, and all of them report the same shares. Click a name for that filer’s whole footprint across every SPAC it has declared a stake in.
News
company wires and the financial pressReporting we have matched to this ticker. Headlines belong to the outlets that wrote them.
Show the headlines
- Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.
Business Wireundated by the source
- AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes
GlobeNewswireNov 13, 2025
Sources on file
harvested pages, kept in fullEvery public page we have read about this company, stored in full so a source can never go missing.
Show the sources
35 full SEC filing texts archived — searchable, never lost.
- Vault note — AEON (Priveterra Acquisition Corp.)
vault-note · /vault/tickers/AEON
- Vault deal note — AEON Biopharma, Inc. (AEON)
vault-note · /vault/deals/aeon-biopharma-inc
- AEON Biopharma Announces Fundraise Totaling Up to ~$22
news · globenewswire.com
- AEON Biopharma plans $11M equity and warrant raise | AEON IPO Registration (S-1)
news · stocktitan.net
- Activating the full potential of therapeutic botulinum toxin | AEON Biopharma
company-site · aeonbiopharma.com
In plain English
tap a term to open itEvery piece of jargon this page could have used, and what it actually means.
Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected
A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Broker action datethe day your broker needs the instruction — earlier than the official date
Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Trust discountbuying below the cash held for you
Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
Pro-forma equitywhat the company is valued at once the deal closes
The combined company's equity value assuming the announced terms and the redemptions that have actually happened.
ARShow much upside you get per unit of downside
SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.
Outside datethe contractual long-stop for closing the deal
A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.
Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since
A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.
Ask the brain
from its filingsData provenance & audit trail5 internal entries
Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.
admitted from EDGAR's QUARTERLY FORM INDEX, walked without any SIC filter. The SIC 6770 census could not reach this registrant: EDGAR reassigns a shell's SIC the day it stops being one, and this CIK now files under 2834 (Pharmaceutical Preparations). The screen found it by filing SHAPE instead — S-1 2021-01-21 → 8-A12B 2021-02-08 → 424B4 2021-02-11 — which nothing rewrites. Admission rule: src/lib/universe-admit.ts. SIC 2834 + self-described blank check in 424B4 0001104659-21-019977; 424B 0001104659-21-019977 priced 2021-02-11 under S-1 0001104659-21-006353 (file 333-252310, an offering for cash); common ticker AEON off 8-K 0001104659-23-083191 (2023-07-24); lifecycle EXITED. The pricing prospectus was filed under SEC file number 333-252310, which belongs to S-1 0001104659-21-006353 (2021-01-21) — a registration of shares sold for CASH, which is what makes it an IPO rather than merger consideration. Blank-check status from the registrant's own first-person sentence in that prospectus (EDGAR full-text search, 424B4 2021-02-11). Ending PROVEN, not inferred: CLOSED per 8-K 0001104659-23-084851 (2023-07-27) — 8-K item 5.06 "Change in Shell Company Status" (EDGAR item index, items: 1.01,2.01,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,8.01,9.01). EDGAR now files this CIK as "AEON Biopharma, Inc." — the SPAC's own name is kept here and the successor is the target. ipoSizeM and deadline left NULL: gross-proceeds prose conflates the over-allotment with the offering, and a charter deadline belonging to a vehicle that has ended is a date nobody can act on. ipoDate is the 424B pricing date.
sponsor "Priveterra Sponsor, LLC" sourced from prospectus definition (10-K/A) acc 0001104659-23-042256.
[CLOSED-RENAME] EDGAR CIK 0001837607 records "Priveterra Acquisition Corp." ending 2023-07-24; the registrant continues as "AEON Biopharma, Inc.". The rename is the SEC's own record of what the vehicle became, keyed by CIK. Closed 2023-07-24. No deal value is set — a rename says what was acquired, never for how much. No date column is set: Deal has announcedAt, voteDate and expectedCloseAt and nowhere to record an actual close, so the SEC's date is kept here until that column exists. [DEAL-STRUCTURE-MINED] pipeSizeM=7, minCashM=40 from primary filings (0001104659-23-076531, 0001104659-23-053372).
OTHER -> BIOTECH, on S-4/A 0001104659-23-053372: "AEON Biopharma, Inc., a Delaware corporation (“AEON”), pursuant to which Merger Sub will merge with and into AEON, with AEON surviving as a wholly-o"
pipeBasis set to UNSOURCED: the size came from the research seed / an earlier record and no filing we hold states it — surfaces now label it "unsourced"; an LLM re-read to FILED replaces this when credits allow